Related Experiment Video
Updated: Jul 9, 2025
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
In Vitro Characterization of the Bacteria-derived Hypoxia-selective Cytotoxin BE-43547
Morten Busk1,2, Peter P Eggertsen3,4, Jens Overgaard3
1Experimental Clinical Oncology, Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; morten@oncology.dk.
Background/Aim:
Hypoxia-activated pro-drugs, such as TH-302, may kill hypoxic treatment-resistant tumor cells, but have failed in clinical trials. This may be related to variable levels of drug-activating reductases. Compounds such as bacteria-derived BE-43547, which target hypoxic cells independently of reductases, may be beneficial. This study characterized the in vitro potency and hypoxia selectivity of BE-43547 and TH-302.
Materials And Methods:
Tumor cells were exposed to different oxygenation levels in the presence/absence of drug, and survival was quantified using total cell number (BE-43547) or clonogenic survival (BE-43547 and TH-302) assays. Half-maximal inhibitory concentration (IC50) values and the hypoxia-cytotoxicity-ratio (HCR: normoxic IC50/hypoxic IC50) were determined from dose-response curves. Finally, both drugs were tested in spheroids exposed to 20% or 0% O2 for 24 h followed by assessment of clonogenic survival.
Results:
BE-43547 was highly potent and displayed little inter-cell line variability. Strongly enhanced cytotoxicity was observed under oxygen-restricted conditions with HCR's of ~100 and ~20 after 24 h of treatment with 0 or 0.5% O2, respectively. Reducing treatment time somewhat reduced hypoxia selectivity. Hypoxia selectivity was observed regardless of whether the drug was added before or during the hypoxic challenge. TH-302 IC50 values varied 10-fold under oxic conditions, whereas those of the anoxic-to-normoxic HCR varied from 15 to 88. Both BE-43547 and TH-302 were unable to completely sterilize anoxic incubated spheroids.
Conclusion:
BE-43547 is highly hypoxia-selective, and unlike TH-302, displayed minimal variability between cell lines, suggesting that BE-43547 targets a fundamental feature/target that is only present, or of survival importance, during hypoxia. Spheroid experiments suggested inadequate tissue penetrability, which may be overcome by designing novel drug analogs.
Insights
Bacteria-derived BE-43547 shows high hypoxia selectivity and minimal variability, unlike TH-302. This suggests BE-43547 targets a hypoxia-specific feature, offering potential for cancer treatment.
Area of Science:
- Oncology
- Hypoxia research
- Drug discovery
Background:
- Hypoxia-activated pro-drugs like TH-302 have failed in clinical trials due to variable reductase levels.
- Bacteria-derived BE-43547 targets hypoxic cells independently of reductases, showing promise.
Purpose of the Study:
- To characterize the in vitro potency and hypoxia selectivity of BE-43547 and TH-302.
- To compare the efficacy of BE-43547 and TH-302 against hypoxic tumor cells.
Main Methods:
- Tumor cells were exposed to varying oxygen levels and drug concentrations.
- Cell survival was quantified using total cell count and clonogenic assays.
- Hypoxia-cytotoxicity-ratio (HCR) was determined to assess drug selectivity.
Main Results:
- BE-43547 demonstrated high potency and low inter-cell line variability.
- BE-43547 exhibited strong hypoxia selectivity with HCRs of ~100 and ~20 at 0% and 0.5% O2, respectively.
- TH-302 showed significant variability in IC50 values and HCRs across cell lines.
Conclusions:
- BE-43547 is highly hypoxia-selective with minimal variability, suggesting a fundamental hypoxia-specific target.
- BE-43547's potential for cancer therapy is highlighted, though tissue penetrability needs improvement.
- Novel drug analogs may overcome limitations in tissue penetration for BE-43547.
